INS and Hypoglycemia: Therapy has been based on insulin or drugs that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reducing hepatic glucose production (biguanides), delaying digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors), or improving insulin action in thiazolidinediones(Grossman et al., 2013 ▶).Unfortunately, all of these therapies have various side effects such as gastrointestinal upset, weight changes, hypoglycemia, joint stiffness, kidney complications, and skin alterations(Nathan,2007 ▶; Soccio et al., 2014 ▶).